India Case Study: Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On
This article was originally published in PharmAsia News
Three years after Novartis and MSD launched their DPP-4 inhibitors in India, PharmAsia News takes a closer look at who will come out on top.
You may also be interested in...
MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names
SAN FRANCISCO - Western companies expanding in emerging markets are likely to distinguish themselves from competitors by successful execution and understanding of local markets, more so than by broad strategic differences, according to participants on a panel on Big Pharma perspectives on emerging markets at Elsevier Business Intelligence's PharmAsia Summit, held Oct. 26 in San Francisco
MUMBAI - Marketing of patented and branded drugs is a relatively new concept in India but going by the initial strategies put into play by multinational companies - most notably for the DPP-4 inhibitors Januvia (sitagliptin), Galvus (vildagliptin) and Onglyza (saxagliptin) - it has all the ingredients of blowing up into an all out war in the race to capture the mind recall of doctors